Does CANAGLIFLOZIN Cause Hypovolaemia? 48 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 48 reports of Hypovolaemia have been filed in association with CANAGLIFLOZIN (INVOKANA). This represents 0.2% of all adverse event reports for CANAGLIFLOZIN.
48
Reports of Hypovolaemia with CANAGLIFLOZIN
0.2%
of all CANAGLIFLOZIN reports
2
Deaths
20
Hospitalizations
How Dangerous Is Hypovolaemia From CANAGLIFLOZIN?
Of the 48 reports, 2 (4.2%) resulted in death, 20 (41.7%) required hospitalization, and 1 (2.1%) were considered life-threatening.
Is Hypovolaemia Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for CANAGLIFLOZIN. However, 48 reports have been filed with the FAERS database.
What Other Side Effects Does CANAGLIFLOZIN Cause?
Diabetic ketoacidosis (3,413)
Toe amputation (2,193)
Osteomyelitis (2,146)
Acute kidney injury (1,853)
Fungal infection (1,385)
Gangrene (1,081)
Weight decreased (1,014)
Cellulitis (1,007)
Urinary tract infection (920)
Diabetic foot infection (832)
What Other Drugs Cause Hypovolaemia?
FUROSEMIDE (346)
METFORMIN (281)
EMPAGLIFLOZIN (150)
SPIRONOLACTONE (123)
DEXAMETHASONE (117)
HYDROCHLOROTHIAZIDE (94)
PREDNISONE (91)
LISINOPRIL (86)
METOPROLOL (84)
ACETAMINOPHEN (77)
Which CANAGLIFLOZIN Alternatives Have Lower Hypovolaemia Risk?
CANAGLIFLOZIN vs CANAGLIFLOZIN\METFORMIN
CANAGLIFLOZIN vs CANAKINUMAB
CANAGLIFLOZIN vs CANDESARTAN
CANAGLIFLOZIN vs CANDESARTAN CILEXETIL
CANAGLIFLOZIN vs CANDESARTAN CILEXETIL\HYDROCHLOROTHIAZIDE